Monte Rosa Therapeutics logo
GLUEMonte Rosa Therapeutics
Trade GLUE now
Monte Rosa Therapeutics primary media

About Monte Rosa Therapeutics

Monte Rosa Therapeutics (NASDAQ:GLUE) is dedicated to advancing the field of molecular degradation to develop innovative therapies for patients with diseases previously thought undruggable. Specializing in using small molecules to degrade disease-causing proteins, the company is at the forefront of creating a pipeline of projects aimed at a range of diseases, including cancer. Monte Rosa is driven by its objective to harness the power of its proprietary platform to bring life-changing treatments to those in urgent need, continually pushing the boundaries of what is possible in targeted therapy.

What is GLUE known for?

Snapshot

Public US
Ownership
2019
Year founded
133
Employees
Boston, United States
Head office
1 of 1
US Rank
Unknown
Sector
N/A
Sector rank
Loading Map...

Operations

All Locations
Boston, US

Products and/or services of Monte Rosa Therapeutics

  • Development of molecular glue degraders designed to eliminate undruggable proteins associated with various cancers.
  • Research in targeted protein degradation using small molecules to modulate protein levels for therapeutic purposes.
  • Creation of a proprietary platform, QuEEN, for the discovery and development of novel E3 ligases.
  • Partnerships with pharmaceutical companies to advance the development and commercialization of targeted therapies.
  • Investment in precision medicine initiatives to tailor treatments to individual genetic profiles, improving efficacy and reducing side effects.
  • Engagement in various oncology-focused clinical trials to validate the effectiveness of novel therapeutic approaches.

Monte Rosa Therapeutics executive team

  • Dr. Markus Warmuth M.D.President, CEO & Director
  • Mr. Philip Nickson J.D., Ph.D.Chief Business & Legal Officer
  • Mr. Filip Janku M.D., Ph.D.Chief Medical Officer
  • Ms. Jennifer ChampouxChief Operating Officer
  • Dr. John C. Castle Ph.D.Chief Data & Information Officer
  • Dr. Sharon Townson Ph.D.Chief Scientific Officer
  • Mr. Andrew FunderburkSenior VP and Head of IR & Strategic Finance
  • Mr. Magnus Walter DPHILSenior Vice President of Drug Discovery
  • Mr. Edmund DunnSenior VP & Corporate Controller

Connect with us

Disclaimer

Grafa is not a financial advisor. You should seek independent, legal, financial, taxation or other advice that relate to your unique circumstances.

Grafa is not liable for any loss caused, whether due to negligence or otherwise arising from the use of or reliance on the information provided directly or indirectly, by use of this platform.